Table II.

Details of the patient population analysed before and after HIFU and Salvage RT.

Patient number	Age	Gleason score at biopsy before HIFU	PSA at HIFU (ng/mL)	PSA at recurrence after HIFU (ng/mL)	Hormone therapy	PET choline on prostate	Time between HIFU and salvage RT (months)	Dose to the prostate/ seminal vesicles/ pelvic lymph nodes (Gy)	Clinical status at last follow-up control
1	78	7 (3 + 4)	4.8	4.00	Yes	Positive	45	71.4/65.5/−	Biochemical non-evidence of disease
2	63	7 (3 + 4)	60	10.46	No	Positive	59	74.2/65.5/51.8	Biochemical non-evidence of disease
3	72	7 (4 + 3)	4.76	6.28	Yes	Positive	22	74.2/65.5/51.8	Biochemical non-evidence of disease
4	60	6 (3 + 3)	11	7.49	No	Positive	43	74.2/65.5/51.8	Metastatic lymph node disease
5	85	7 (4 + 3)	9	7.64	Yes	Positive	37	74.2/65.5/51.8	Biochemical non-evidence of disease
6	63	8 (5 + 3)	4.8	2.30	Yes	Positive	14	71.4/65.5/51.8	Metastatic bone disease
7	74	9 (5 + 4)	3.16	64.02	Yes	Positive	8	71.4/65.5/51.8	Metastatic bone disease
8	67	6 (3 + 3)	12	27.86	No	Positive	71	74.2/65.5/51.8	Biochemical non-evidence of disease
9	62	7 (3 + 4)	21	2.00	No	Positive	13	71.4/65.5/−	Biochemical non-evidence of disease
10	65	6 (3 + 3)	3.3	6.74	No	Positive	20	71.4/65.5/−	Biochemical non-evidence of disease
11	71	7 (3 + 4)	4.5	4.50	Yes	Positive	34	74.2/65.5/51.8	Biochemical non-evidence of disease
12	68	7 (3 + 4)	5.75	4.59	No	Positive	10	74.2/65.5/−	Biochemical non-evidence of disease
13	53	6 (3 + 3)	5	3.04	No	Positive	38	71.4/65.5/−	Biochemical non-evidence of disease
14	70	6 (3 + 3)	35	3.60	No	Positive	25	71.4/65.5/−	Biochemical non-evidence of disease
15	65	6 (3 + 3)	11	5.25	No	Positive	30	71.4/65.5/−	Biochemical non-evidence of disease